5 Key Takeaways

• 1

  Plasma microRNA signatures may aid in early detection of Alzheimer's disease and predict progression from mild cognitive impairment to Alzheimer's.

• 2

  The study analyzed plasma samples from 803 participants, including those with early MCI, late MCI, AD, and cognitively normal controls.

• 3

  Distinct miRNA signatures were identified that could predict MCI and AD diagnoses with accuracy comparable to total Tau biomarkers.

• 4

  MiRNA signatures were found to regulate pathways related to synaptic plasticity, mitochondrial dysfunction, and neuroinflammation.

• 5

  Further validation in diverse populations and longitudinal studies is needed to confirm the clinical applicability of these miRNA findings.